Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.46 |
| ▸ | HTR1A | P08908 | 3/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328335 | 1.00 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3HTR1AHTR6 | |
| SCHEMBL3328340 | 1.00 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3HTR1AHTR6 | |
| Oxalic Acid SCHEMBL3321313 | 0.94 | KDM4E (0.44) | SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL3325927 | 0.86 | SLC6A2 (0.48) | SLC6A4SLC6A2SLC6A3HTR1AHTR2C | |
| SCHEMBL3325931 | 0.86 | SLC6A2 (0.48) | SLC6A4SLC6A2SLC6A3HTR1AHTR2C | |
| SCHEMBL3323892 | 0.86 | SLC6A2 (0.48) | SLC6A4SLC6A2SLC6A3HTR1AHTR2C | |
| SCHEMBL3327016 | 0.85 | ALOX15 (0.42) | SLC6A4SLC6A2SLC6A3HTR2CNISCH | |
| SCHEMBL3325173 | 0.85 | ALOX15 (0.42) | SLC6A4SLC6A2SLC6A3HTR2CNISCH | |
| SCHEMBL3327020 | 0.85 | ALOX15 (0.42) | SLC6A4SLC6A2SLC6A3HTR2CNISCH | |
| SCHEMBL3322368 | 0.83 | SLC6A2 (0.40) | SLC6A4SLC6A2SLC6A3HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120858-A1 | Piperidine Derivatives | PFIZER INC. | 2010-05-13 | — | — | US | disclosed |
| EP-2066630-A1 | PIPERIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008023258-A1 | PIPERIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120858-A1 | Piperidine Derivatives | P2RX5, P2RX7, P2RX1 | SLC6A4 1898/4885SLC6A2 2609/4885SLC6A3 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.